| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Applied Materials (NASDAQ:AMAT) Stock Rises After Earnings Beat: AI Drives 53% Revenue Growth | ||
| Do | Why Is Super Micro (NASDAQ:SMCI) Stock Crashing 11%? DOJ Probes China Chip Smuggling Allegations | ||
| Do | What Are Some Online Brokers for Trading Forex and CFDs? Five Platforms Australian Traders Use | ||
| Do | Ardelyx (NDQ:ARDX): Have Investors Lost Sight Of The Long-Term Story? | ||
| Do | ImmunityBio (NDQ:IBRX): The Next Keytruda Or The Next Niche Oncology Drug? Investors Are Excited! | ||
| Do | AMD and Broadcom Rally as Nvidia Falls: Are AI Chip Rivals Gaining Ground? | ||
| Do | Is Xero (ASX:XRO) a Long-Term Buy After Its H1 FY27 Results? | ||
| Do | Clarity Pharmaceuticals (ASX:CU6): Twice the lesions, half the wait. Why the FDA fast tracked CU6's copper scan | ||
| Do | Xero (ASX:XRO) Upgrades Guidance and Announces A$1bn Share Buyback | ||
| Do | Aristocrat (ASX:ALL) The Pokies Business Is Booming. Can Its Online Division Catch Up? | ||
| Do | Orica (ASX:ORI) clocks A$1.06bn EBIT as Digital reshapes the mix | ||
| Do | CoreWeave (NASDAQ:CRWV) 168% Revenue Growth Reignites AI Trade Despite Debt Risk | ||
| Do | GrainCorp (ASX:GNC) The Worst May Be Over as Harvest Volumes Start Rebounding | ||
| Do | G8 Education (ASX:GEM) A 160% Premium Takeover Offer Is on the Table. Is It Enough? | ||
| Do | Pfizer (NYSE:PFE) Is Getting $1.5bn From Blackstone To Fund Its GLP-1 Ambitions | ||
| Do | D-Wave Quantum (NDQ:QBTS): This Quantum Computing Play Grew Revenues By 20%, But Losses Are Growing Too | ||
| Mi | CoreWeave flexes, Nebius tags along … the Neocloud party is back on | ||
| Mi | Lennar Corporation (NYSE: LEN) and NVR (NYSE: NVR) Fall Amidst US Inflation Concerns | ||
| Mi | Nvidia's Jensen Problem Could Cost a Lot More Than a CEO | ||
| Mi | BioMarin Pharmaceutical (NDQ:BMRN): The Market Sees A Mature Slow-Growth Biotech, But Is It Missing The Next Growth Leg? | ||
| Mi | Replimune (NDQ:REPL): Is TUDRIQEV Just A Melanoma Drug, Or The First Validation Of An Entirely New Cancer Treatment Platform? | ||
| Mi | Amplia Therapeutics (ASX:ATX) had outstanding Phase 2 data for narmafotinib in pancreatic cancer! | ||
| Mi | PEXA Group (ASX:PXA) FY27 Margins Are Sliding. Is the Housing Cycle Now the Bigger Risk? | ||
| Mi | Nvidia (NASDAQ:NVDA) Stock Crashes 5.5% as $7.5 Billion China Chip Claims Trigger Fresh Scrutiny | ||
| Mi | Adairs (ASX:ADH) One Weak Division Is Dragging Down the Whole Group |